RSS-Feed abonnieren
DOI: 10.1055/a-2414-1063
The Management of Patients with Extrapulmonary Sarcoidosis in Rheumatology Clinic
Das Management von Patienten mit extrapulmonaler Sarkoidose in der Rheumatologie-Klinik Fundings The authors received no financial support for the research and/or authorship of this article.
Abstract
Background This study aimed to evaluate patients with extrapulmonary and refractory sarcoidosis who were followed up on in our rheumatology clinic for a long follow-up period and to summarise the applications in rheumatology practice.
Materials and Methods The study included patients diagnosed with sarcoidosis at our institution between 2010 and 2022. Patientsʼ age, sarcoidosis diagnosis dates, inflammatory rheumatic disease (iRMD) diagnoses, autoimmune markers, and imaging findings were all evaluated. Estimates were made for cases of glucocorticoid (GC) use and cumulative and mean daily GC exposures.
Results 90 patients with sarcoidosis, 79 (87.8) female and 11 (12.2) male, whose mean age was 56.4±12.4 years, were included. Since 48 (53.3%) of the patients required at least one additional treatment in addition to CS, they were classified as having refractory sarcoidosis and followed up accordingly. While 43 (89%) of the patients received second-line sarcoidosis treatment, it was found that 5 patients were switched to third-line sarcoidosis treatment (p<0.001). Comorbidity distributions of refractory and nonrefractory patients were similar. It was determined that 9 (10%) patients had a history of osteoporotic fracture.
Conclusions In conclusion, it appears critical to develop a detailed patient management plan and a multidisciplinary approach in the early stages of extrapulmonary sarcoidosis management. There is currently no detailed algorithm covering refractory disease definition and treatment practice differences.
Publikationsverlauf
Artikel online veröffentlicht:
24. Oktober 2024
© 2024. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
References
- 1 Jain R, Yadav D, Puranik N. et al. Sarcoidosis: Causes, Diagnosis, Clinical Features, and Treatments. J Clin Med 2020; 9
- 2 Judson MA, Boan AD, Lackland DT. The clinical course of sarcoidosis: presentation, diagnosis, and treatment in a large white and black cohort in the United States. Sarcoidosis, Vasc Diffus lung Dis Off J WASOG 2012; 29: 119-127
- 3 Baughman RP, Field S, Costabel U. et al. Sarcoidosis in America. Analysis Based on Health Care Use. Ann Am Thorac Soc 2016; 13: 1244-1252
- 4 Arkema EV, Grunewald J, Kullberg S. et al. Sarcoidosis incidence and prevalence: a nationwide register-based assessment in Sweden. Eur Respir J 2016; 48: 1690-1699
- 5 Sakthivel P, Bruder D. Mechanism of granuloma formation in sarcoidosis. Curr Opin Hematol 2017; 24: 59-65
- 6 Grunewald J, Grutters JC, Arkema EV. et al. Sarcoidosis. Nat Rev Dis Prim 2019; 5: 45
- 7 Kaiser Y, Eklund A, Grunewald J. Moving target: shifting the focus to pulmonary sarcoidosis as an autoimmune spectrum disorder. Eur Respir J 2019; 54: 1802153
- 8 Hammam N, Evans M, Morgan E. et al. Treatment of Sarcoidosis in Rheumatology Practices: Data From the American College of Rheumatologyʼs Rheumatology Informatics System for Effectiveness Registry. Arthritis Care Res (Hoboken) 2022; 74: 371-376
- 9 Rizzato G, Palmieri G, Agrati AM. et al. The organ-specific extrapulmonary presentation of sarcoidosis: a frequent occurrence but a challenge to an early diagnosis. A 3-year-long prospective observational study. Sarcoidosis, Vasc Diffus lung Dis Off J WASOG 2004; 21: 119-126
- 10 Hu X, Carmona EM, Yi ES. et al. Causes of death in patients with chronic sarcoidosis. Sarcoidosis, Vasc Diffus lung Dis Off J WASOG 2016; 33: 275-280
- 11 Judson MA. The Diagnosis of Sarcoidosis. Clin Chest Med 2008; 29: 415-427
- 12 Judson MA, Baughman RP, Teirstein AS. et al. Defining organ involvement in sarcoidosis: the ACCESS proposed instrument. ACCESS Research Group. A Case Control Etiologic Study of Sarcoidosis. Sarcoidosis, Vasc Diffus lung Dis Off J WASOG 1999; 16: 75-86
- 13 Korsten P, Strohmayer K, Baughman RP. et al. Refractory Pulmonary Sarcoidosis. Clin Pulm Med 2016; 23: 67-75
- 14 Soto-Gomez N, Peters JI, Nambiar AM. Diagnosis and Management of Sarcoidosis. Am Fam Physician 2016; 93: 840-848
- 15 Hunninghake GW, Costabel U, Ando M. et al. ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. Sarcoidosis, Vasc Diffus lung Dis Off J WASOG 1999; 16: 149-173
- 16 Baughman RP, Teirstein AS, Judson MA. et al. Clinical Characteristics of Patients in a Case Control Study of Sarcoidosis. Am J Respir Crit Care Med 2001; 164: 1885-1889
- 17 De Vries F, Bracke M, Leufkens HGM. et al. Fracture risk with intermittent high-dose oral glucocorticoid therapy. Arthritis Rheum 2007; 56: 208-214
- 18 Sweiss NJ, Lower EE, Mirsaeidi M. et al. Rituximab in the treatment of refractory pulmonary sarcoidosis. Eur Respir J 2014; 43: 1525-1528
- 19 Pereira CAC, Dornfeld MC, Baughman R. et al. Clinical phenotypes in sarcoidosis. Curr Opin Pulm Med 2014; 20: 496-502
- 20 Arkema EV, Cozier YC. Epidemiology of sarcoidosis: current findings and future directions. Ther Adv Chronic Dis 2018; 9: 227-240
- 21 Valeyre D, Prasse A, Nunes H. et al. Sarcoidosis. Lancet 2014; 383: 1155-1167
- 22 Sellarés J, Francesqui J, Llabres M. et al. Current treatment of sarcoidosis. Curr Opin Pulm Med 2020; 26: 591-597
- 23 McKinzie BP, Bullington WM, Mazur JE. et al. Efficacy of Short-Course, Low-Dose Corticosteroid Therapy for Acute Pulmonary Sarcoidosis Exacerbations. Am J Med Sci 2010; 339: 1-4
- 24 Schutt AC, Bullington WM, Judson MA. Pharmacotherapy for pulmonary sarcoidosis: A delphi consensus study. Respir Med 2010; 104: 717-723
- 25 Ussavarungsi K, Gerke AK. Approach to tapering antisarcoidosis therapy. Curr Opin Pulm Med 2019; 25: 526-532
- 26 Grutters JC, van den Bosch JMM. Corticosteroid treatment in sarcoidosis. Eur Respir J 2006; 28: 627-636
- 27 Al-Kofahi K, Korsten P, Ascoli C. et al. Management of extrapulmonary sarcoidosis: challenges and solutions. Ther Clin Risk Manag 2016; 12: 1623-1634
- 28 Rice JB, White A, Lopez A. et al. High-Cost Sarcoidosis Patients in the United States: Patient Characteristics and Patterns of Health Care Resource Utilization. J Manag Care Spec Pharm 2017; 23: 1261-1269
- 29 Fang C, Zhang Q, Wang N. et al. Effectiveness and tolerability of methotrexate in pulmonary sarcoidosis: A single center real-world study. Sarcoidosis, Vasc Diffus lung Dis Off J WASOG 2019; 36: 217-227
- 30 Vorselaars ADM, Wuyts WA, Vorselaars VMM. et al. Methotrexate vs Azathioprine in Second-line Therapy of Sarcoidosis. Chest 2013; 144: 805-812
- 31 Bitoun S, Bouvry D, Borie R. et al. Treatment of neurosarcoidosis. Neurology 2016; 87: 2517-2521
- 32 Moravan M, Segal BM. Treatment of CNS sarcoidosis with infliximab and mycophenolate mofetil. Neurology 2009; 72: 337-340
- 33 Sakkat A, Cox G, Khalidi N. et al. Infliximab therapy in refractory sarcoidosis: a multicenter real-world analysis. Respir Res 2022; 23: 54
- 34 James WE, Baughman R. Treatment of sarcoidosis: grading the evidence. Expert Rev Clin Pharmacol 2018; 11: 677-687
- 35 Alnaimat F, Al Oweidat K, Alrwahdeh A. et al. Sarcoidosis in Jordan: A Study of the Clinical Phenotype and Disease Outcome. Arch Rheumatol 2020; 35: 226-238
- 36 Soto-Gomez N, Peters JI, Nambiar AM. Diagnosis and management of sarcoidosis. Am Fam Physician 2016; 93: 840-848
- 37 Bussinguer M, Danielian A, Sharma OP. Cardiac Sarcoidosis: Diagnosis and Management. Curr Treat Options Cardiovasc Med 2012; 14: 652-664
- 38 Krause ML, Cooper LT, Chareonthaitawee P. et al. Successful use of rituximab in refractory cardiac sarcoidosis. Rheumatology 2016; 55: 189-191
- 39 Ho JSY, Chilvers ER, Thillai M. Cardiac sarcoidosis – an expert review for the chest physician. Expert Rev Respir Med 2019; 13: 507-520